Zevalin和Bexxar在放射免疫治疗中的研究进展  

Current research of Zevalin and Bexxar in the field of radioimmunotherapy

作　　者：刘钊[1] 李军民[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院血液科,上海200025

出　　处：《复旦学报（医学版）》2009年第6期786-788,共3页Fudan University Journal of Medical Sciences

摘　　要：应用核素偶联的单抗进行放射免疫治疗已经被公认为新一代治疗难治非霍奇金淋巴瘤(non-Hodgkin’slymphoma,NHL)的有效手段。90Y-ibritumomab tiuxetan(Zevalin)和131I-tositumomab tiuxetan(Bexxar)等CD20核素标记的单克隆抗体在难治或复发的滤泡型/低度恶性或转化型非霍奇金淋巴瘤的治疗研究中取得显著成效。本文将对Zevalin和Bexxar的作用机制、治疗方法、临床研究及安全性作一个回顾性的总结及展望。Radioimmunotherapy using monoclonal antibodies incorporated with radionuclide has been showed to be an effective agent for refractory non-Hodgkin＇s lymphoma （NHL）. Many anti-CD20 antibodies labeled with radionucIide, such as ^90 Y-ibritumomab tiuxetan （Zevalin） and ^131 I-tositumomab tiuxetan （Bexxar）, have been reported to be effective for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed NHL. This review summarizes the current advance in clinical trials and studies of Zevalin and Bexxar for the treatment of NHL patients.

关 键 词：非霍奇金淋巴瘤 放射免疫治疗 放射同位素 CD20 

分 类 号：R730.58[医药卫生—肿瘤]